Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare salivary cancer, histologically resembling to secretory carcinoma of the breast. In 2017 World Health Organization reported MASC is a new salivary cancer subtype. The aim of this article is to collect and analyze data about...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-07-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242559955599360 |
|---|---|
| author | A. V. Ignatova A. M. Mudunov S. О. Podvyaznikov Yu. V. Alymov |
| author_facet | A. V. Ignatova A. M. Mudunov S. О. Podvyaznikov Yu. V. Alymov |
| author_sort | A. V. Ignatova |
| collection | DOAJ |
| description | Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare salivary cancer, histologically resembling to secretory carcinoma of the breast. In 2017 World Health Organization reported MASC is a new salivary cancer subtype. The aim of this article is to collect and analyze data about MASC, particularly clinical, histological and molecular profile, to evaluate targeted therapy effects. We discuss a case report of dramatic and durable response with entrectinib and the development of acquired resistance in an NTRK3-fusion positive salivary cancer, detected by next-generation sequencing. Next-generation sequencing as a comprehensive molecular profiling, that helps to investigate molecular profile of rare tumors and gives an opportunity to use an effective therapeutic options. Identifying ETV6-NTRK3 positive MASC provides a better prognosis for metastatic disease by using a novel effective targeted therapy with tyrosine kinase inhibitors (entrectinib, larotrectinib). Despite a durable and dramatic response, we showed an interesting case of the development of acquired resistance to tyrosine kinase inhibitors mediated by the appearance of a novel NTRK3 G623R mutation. Finally, we believe in great perspectives of comprehensive molecular profiling and targeted therapy for rare malignancies with NTRK gene fusions, including second-generation tyrosine kinase inhibitors. |
| format | Article |
| id | doaj-art-ae69646d4aaa47b785068db23ae5b018 |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2020-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-ae69646d4aaa47b785068db23ae5b0182025-08-20T03:59:48ZrusABV-pressОпухоли головы и шеи2222-14682411-46342020-07-01102697810.17650/2222-1468-2020-10-2-69-78395Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)A. V. Ignatova0A. M. Mudunov1S. О. Podvyaznikov2Yu. V. Alymov3Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; RUDN UniversityRussian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaMammary analogue secretory carcinoma (MASC) of the salivary gland is a rare salivary cancer, histologically resembling to secretory carcinoma of the breast. In 2017 World Health Organization reported MASC is a new salivary cancer subtype. The aim of this article is to collect and analyze data about MASC, particularly clinical, histological and molecular profile, to evaluate targeted therapy effects. We discuss a case report of dramatic and durable response with entrectinib and the development of acquired resistance in an NTRK3-fusion positive salivary cancer, detected by next-generation sequencing. Next-generation sequencing as a comprehensive molecular profiling, that helps to investigate molecular profile of rare tumors and gives an opportunity to use an effective therapeutic options. Identifying ETV6-NTRK3 positive MASC provides a better prognosis for metastatic disease by using a novel effective targeted therapy with tyrosine kinase inhibitors (entrectinib, larotrectinib). Despite a durable and dramatic response, we showed an interesting case of the development of acquired resistance to tyrosine kinase inhibitors mediated by the appearance of a novel NTRK3 G623R mutation. Finally, we believe in great perspectives of comprehensive molecular profiling and targeted therapy for rare malignancies with NTRK gene fusions, including second-generation tyrosine kinase inhibitors.https://ogsh.abvpress.ru/jour/article/view/529mammary analogue secretory carcinomaetv6-ntrk3next-generation sequencingfluorescent in situ hybridizationimmunohistochemistrypolymerase chain reactiontyrosine kinase inhibitorsentrectiniblarotrectinib |
| spellingShingle | A. V. Ignatova A. M. Mudunov S. О. Podvyaznikov Yu. V. Alymov Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) Опухоли головы и шеи mammary analogue secretory carcinoma etv6-ntrk3 next-generation sequencing fluorescent in situ hybridization immunohistochemistry polymerase chain reaction tyrosine kinase inhibitors entrectinib larotrectinib |
| title | Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) |
| title_full | Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) |
| title_fullStr | Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) |
| title_full_unstemmed | Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) |
| title_short | Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review) |
| title_sort | mammary analogue secretory carcinoma of the salivary gland with ntrk fusions new approaches for diagnostics and targeted therapy review |
| topic | mammary analogue secretory carcinoma etv6-ntrk3 next-generation sequencing fluorescent in situ hybridization immunohistochemistry polymerase chain reaction tyrosine kinase inhibitors entrectinib larotrectinib |
| url | https://ogsh.abvpress.ru/jour/article/view/529 |
| work_keys_str_mv | AT avignatova mammaryanaloguesecretorycarcinomaofthesalivaryglandwithntrkfusionsnewapproachesfordiagnosticsandtargetedtherapyreview AT ammudunov mammaryanaloguesecretorycarcinomaofthesalivaryglandwithntrkfusionsnewapproachesfordiagnosticsandtargetedtherapyreview AT sopodvyaznikov mammaryanaloguesecretorycarcinomaofthesalivaryglandwithntrkfusionsnewapproachesfordiagnosticsandtargetedtherapyreview AT yuvalymov mammaryanaloguesecretorycarcinomaofthesalivaryglandwithntrkfusionsnewapproachesfordiagnosticsandtargetedtherapyreview |